← Back to contracts

Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma

US National Cancer Institute grant open #nih-5R01CA257009-05

Summary

ABSTRACT Glioblastoma’s (GBM) invasive nature is part of the reason this primary brain tumor results in near 100% mortality. Even with surgical resection, radiation, and chemotherapy, the median survival remains of only 12-15 months. Tumor invasion make complete surgical resection difficult leading to local recurrence within 2 centimeters of the original tumor in 90-95% of patients. Most systemically delivered chemotherapy agents are ineffective against GBM because they cannot reach the brain at therapeutic concentrations due to the blood- brain barrier. The blood-brain barrier is a highly sel

Tunable Temporal Drug Release for Optimize…
Onboard